Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Merck has informed that the following decisions taken at the meeting of the Board of Directors of the Company on 28 November 2018, all of which are conditional upon the consummation of the transactions contemplated by the India Sale and Purchase Agreement, dated April 19, 2018 (the India SAPA), by and among, Merck Internationale Beteiligungen GmbH, Chemitra Gesellschaft mit beschrankter Haftung, Emedia Export Company mit beschrankter Haftung (together, the Sellers), Merck KGaA and Procter & Gamble Overseas India B.V (Acquirer) (India SAPA Closing): Resignation of Zoe Tang as a director on the Board; Resignation of N. Krishnan as the Chief Financial Officer of the Company and as a director on the Board, Resignation of Vikas R. Gupta as the General Counsel and Company Secretary of the Company; Resignation of H.C.H. Bhabha as an independent director on the Board; Proposal for appointment of Amit Gupta as an additional director on the Board; Share Transfer from the Sellers to the Acquirer. Further, the Board was informed that the Share Transfer is subject to satisfaction of certain conditions precedent, including receipt of statutory and regulatory approvals, as well as completion by Merck KGaA, Germany, of a sale globally of its consumer health business to The Procter & Gamble Company (and its affiliates) through one or more sale and purchase agreements (the Global Transaction).
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |